{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:04:54Z","timestamp":1790935494777,"version":"4.1.0"},"reference-count":24,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunotoxicology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1080\/15376510802312464","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T02:52:28Z","timestamp":1222915948000},"page":"315-335","source":"Crossref","is-referenced-by-count":54,"title":["Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene Inserts"],"prefix":"10.1080","volume":"5","author":[{"given":"Rebecca L.","family":"Sheets","sequence":"first","affiliation":[{"name":"Vaccine Research Center, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Stein","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Bailer","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charla","family":"Andrews","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Nason","sequence":"additional","affiliation":[{"name":"Biostatistics Research Branch, NIH\/NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[{"name":"Bridge Laboratories, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Koo","sequence":"additional","affiliation":[{"name":"Bridge Laboratories, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Trotter","sequence":"additional","affiliation":[{"name":"Althea Technologies, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Duffy","sequence":"additional","affiliation":[{"name":"Althea Technologies, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Manetz","sequence":"additional","affiliation":[{"name":"MedImmune, Inc., Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Gomez","sequence":"additional","affiliation":[{"name":"PRTM, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2008,10,20]]},"reference":[{"key":"CIT0001","first-page":"470","volume":"71","author":"Beck D.W.","year":"1979","journal-title":"AJCP"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1086\/509258"},{"key":"CIT0003","volume-title":"Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications","author":"CBER","year":"2006"},{"key":"CIT0004","first-page":"331","volume-title":"Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration","author":"Chang P.Y.","year":"2007"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030025"},{"key":"CIT0006","volume-title":"Press release: Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial","author":"Crucell","year":"2006"},{"key":"CIT0007","unstructured":"Crucell. (2006b) http:\/\/investors.crucell.com\/C\/132631\/PR\/200612\/1094140_5_5.html Press release: Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study 2006 December 19, 2006."},{"key":"CIT0008","unstructured":"GenVec. (2007) http:\/\/www.genvec.com\/download\/press\/GNVC_Ad35CLINICALTRIAL%20Release%20_FINALOUT__062007_1.pdf Press release: First Ad35-Based HIV-1 Vaccine Enters Phase 1 Clinical Trial at NIH 2007 June 21, 2007."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1086\/509259"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/10430340152712638","volume":"13","author":"Harvey B.G.","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF01788133","volume":"67","author":"Jaeger U.","year":"1993","journal-title":"Ann. Hematol."},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1152\/ajplegacy.1939.125.3.521","volume":"125","author":"Lee R.C.","year":"1939","journal-title":"Am. J. Physiol."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.urology.2005.04.041","volume":"66","author":"Malaeb B.S.","year":"2005","journal-title":"Urology"},{"issue":"8","key":"CIT0014","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2006-04-008532","volume":"108","author":"Parker A.L.","year":"2006","journal-title":"Blood"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1089\/10430340152712719"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/toxsci\/kfj169","volume":"91","author":"Sheets R.L.","year":"2006","journal-title":"Toxicol. Sci."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfj170"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/35046108"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/JVI.79.1.547-553.2005","volume":"79","author":"Sullivan N.J.","year":"2005","journal-title":"J. Virol."},{"issue":"6","key":"CIT0020","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","volume":"3","author":"Sullivan N.J.","year":"2006","journal-title":"PLoS Med."},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"10950","DOI":"10.1128\/JVI.01458-06","volume":"80","author":"Sun Y.","year":"2006","journal-title":"J Virol."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-062117"},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1128\/JVI.01749-06","volume":"80","author":"Thorner A.R.","year":"2006","journal-title":"J. Virol."},{"key":"CIT0024","volume-title":"Good Laboratory Practices for Nonclinical Laboratory Studies","year":"2007"}],"container-title":["Journal of Immunotoxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15376510802312464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T06:56:45Z","timestamp":1557817005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15376510802312464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,10,20]]},"published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1080\/15376510802312464"],"URL":"https:\/\/doi.org\/10.1080\/15376510802312464","relation":{},"ISSN":["1547-691X","1547-6901"],"issn-type":[{"value":"1547-691X","type":"print"},{"value":"1547-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}